RxDoctor Payments Data

Robert Boyle, APRN

Psychiatric/Mental Health · Waterloo, IANPI 1346557550

Payments from drug & device makers

$826in general payments, 2019–2025

Across 30 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$319
  • Johnson & Johnson$182
  • Axsome Therapeutics, Inc.$104
  • Otsuka America Pharmaceutical, Inc.$75
  • Neurocrine Biosciences, Inc.$51
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$26
  • plus $70 from 4 others

What the payments were for

  • Food & beverage$826100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$826 in reported general payments places this provider in the 50th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$34,556
Medicare patients
91
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$96,328
Abilify MaintenaAripiprazole12$33,418
VraylarCariprazine Hcl21$29,857
RexultiBrexpiprazole16$26,010
TrintellixVortioxetine Hydrobromide24$15,173
VyvanseLisdexamfetamine Dimesylate20$7,588
Asenapine Maleate14$5,414
Bupropion XlBupropion Hcl103$2,362
Aripiprazole72$2,247
Venlafaxine Hcl ErVenlafaxine Hcl122$2,149
Buspirone Hcl116$1,411
Trazodone Hcl125$1,301
Oxcarbazepine16$1,204
Fluvoxamine Maleate28$1,163
Lamotrigine70$950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$51$96,32813 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$75$59,42828 claims
AbbVieVraylar$319$29,85721 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$21$22,76144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →